Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Frederick Smith (NPI 1730185935)

Field	Value
Entity Type	Individual
Organization	Frederick Smith
Address	5454 Wisconsin Ave
City	Chevy Chase
State	MD
ZIP	20815
Taxonomy	Medical Oncology Physician
NPI Enumerated	June 22, 2005

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

FREDERICK SMITH is a Medical Oncology Physician in CHEVY CHASE, MD who has been enumerated since 2005-06-22 (~21 years ago) and has $2.7M in lifetime Medicare revenue on file; there is no Medicaid billing on file for this provider. The absence of any Medicaid claims makes this provider effectively single-payer (Medicare) in the available dataset, concentrating reimbursement exposure to Medicare policies and pricing.

Revenue is highly concentrated in a few high-cost drugs and an evaluation-and-management code: the precomputed top 3 Medicare codes (J9271, J0897, 99214) account for 79.1% of this provider's total Medicare revenue. J9271 accounts for $1.2M (43.4% of Medicare revenue), J0897 accounts for $801.4K (29.7%), and 99214 accounts for $162.1K (6.0%), indicating that a small set of items drive the majority of dollars.

The provider’s code mix and top-revenue items indicate an infusion- and oncology-centered practice model: high-revenue biologic/oncology drugs J9271 (pembrolizumab) and J0897 (denosumab) dominate, and multiple chemotherapy administration codes (96413, 96401, 96402, 96365, 96417) appear in the top 25. This pattern is consistent with an office-based infusion practice that delivers both anticancer agents and supportive-care injections in addition to outpatient E/M visits.

On competitive standing, the provider is an extreme outlier on select codes but more typical on others. J0897 ranks #37 of 10057 (100th percentile; extreme outlier, far above typical national volume), 99214 ranks #3919 of 479517 (99th percentile; extreme outlier, far above typical national volume), while J9271 ranks #171 of 1841 (90th percentile; typical, unremarkable volume), suggesting market-leading volume for denosumab and unusually high E/M visit volume relative to peers but only typical pembrolizumab activity among oncology specialists.

Several chemotherapy administration codes show materially above-typical activity: 96413 (785 claims, $97.3K; ranks #190 of 7514, 97th percentile; notably above typical national volume) and 96402 (292 claims, $9.1K; ranks #23 of 4765, 100th percentile; extreme outlier, far above typical national volume) both appear in the provider’s top procedures. Those rankings indicate consistent, high-frequency chemotherapy delivery relative to national peers and reinforce the interpretation of an active infusion service line.

The practice shows substantive use of supportive-care biologics and biosimilars: Q5111 (pegfilgrastim-cbqv) generated $116.4K and ranks #14 of 123 (89th percentile), Q5106 (epoetin alfa-epbx) and J0885 (epoetin alfa) also appear in the top 25. This mix of growth-factor agents, epoetins, and iron preparations (J1439, J1437, J1439) suggests bundled supportive-care offerings accompanying cancer treatment and adoption of biosimilar products in the medication mix.

Although E/M codes contribute a smaller share of total dollars than drugs and infusions, visit volumes are notable: 99214 produced $162.1K (6.0% of Medicare revenue) and ranks in the 99th percentile, and 99213 produced $56.3K (2.1%). The combination of high-percentile E/M rankings with dominant drug revenue implies a practice that pairs frequent, moderately complex clinic visits with high-cost in-office drug administration rather than relying primarily on office visits for revenue.

The lack of any Medicaid billing on file ("none below") means there is no observed Medicaid patient flow in this dataset, which has implications for network contracting and patient access analyses. For payer mix and population-based planning, treat this provider as Medicare-focused in the available claims data and consider supplemental data sources if Medicaid participation is material but not captured here.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

38 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	27,200	$40	$1.2M
J0897	Injection, denosumab, 1 mg	42,180	$20	$801.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,460	$110	$162.1K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	1,070	$110	$116.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	790	$120	$97.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	750	$80	$56.3K
J1439	Injection, ferric carboxymaltose, 1 mg	43,500	$1	$43.5K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	560	$70	$37.7K
J1437	Injection, ferric derisomaltose, 10 mg	1,600	$20	$25.6K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	3,780	$10	$22.7K

Showing 1–10 of 38

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 38 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Frederick Smith — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

38 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	60	15,000	$40	$787.6K
J0897	2	340	3,600	$20	$114.4K
Q5111	5	10	930	$110	$92.7K
J1437	44	50	2,800	$20	$75.1K
J3490	8	100	70	$450	$62.1K
J0885	16	20	4,800	$10	$43.2K
J1439	14	40	30,750	$1	$36.2K
Q5106	16	20	4,040	$10	$30K
96413	11	230	200	$110	$29.6K
J9217	70	100	150	$130	$27.3K

Showing 1–10 of 38

Related Providers

Other providers that share a Tax Identification Number (TIN) with Frederick Smith, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Glen Gejerman	NJ	Radiation Oncology Physician	$6.5M	$0
Maryland Oncology Hematology P.A.	MD	Hematology & Oncology Physician	$0	$4.6M
Bhavesh Balar	NJ	Hematology & Oncology Physician	$4.2M	$0
Kashif Ali	MD	Hematology & Oncology Physician	$3.6M	$0
Andrew Mener	MD	Hematology & Oncology Physician	$3.5M	$0
Jason Taksey	MD	Medical Oncology Physician	$3.3M	$0
Kenneth Nahum	NJ	Hematology & Oncology Physician	$3.2M	$0
Frederick Min	MD	Hematology & Oncology Physician	$3.2M	$0
Mohit Narang	MD	Medical Oncology Physician	$3M	$0
Deepnarayan Tiwarri	MD	Hematology & Oncology Physician	$2.6M	$0

Nearby Providers

Other providers in the same ZIP code as Frederick Smith, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Daniel Berinstein	MD	Retina Specialist (Ophthalmology) Physician	$4.3M	$0
Michael Lai	MD	Retina Specialist (Ophthalmology) Physician	$4.2M	$0
Gayatri Reilly	MD	Retina Specialist (Ophthalmology) Physician	$4.1M	$0
Richard Garfinkel	MD	Retina Specialist (Ophthalmology) Physician	$2.4M	$0
John Schreiber	MD	Diagnostic Radiology Physician	$2.3M	$0
Friendship Ambulatory Surgery Center, LLC	MD	Ambulatory Surgical Clinic/Center	$2.2M	$0
David Weng	MD	Medical Oncology Physician	$1.5M	$0
Hyland Cronin	MD	Dermatology Physician	$1.5M	$0
David Wolfe	MD	Rheumatology Physician	$1.4M	$0
Brian Do	MD	Retina Specialist (Ophthalmology) Physician	$1.2M	$0

Frederick Smith — Billing Profile & Reimbursement Data

Sign up for Frederick Smith — Billing Profile & Reimbursement Data policy alerts

Frederick Smith — Billing Profile & Reimbursement Data

Sign up for Frederick Smith — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References